Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.78 | 14.78 | -1.14 | 0.48 |
| FCF Yield | 2.94% | 3.24% | 1.32% | 1.50% |
| EV / EBITDA | 22.79 | 7.45 | 21.52 | 16.17 |
| Quality | ||||
| ROIC | 1.66% | 7.81% | 8.87% | 8.10% |
| Gross Margin | 33.95% | 38.58% | 39.64% | 43.55% |
| Cash Conversion Ratio | 2.45 | 0.57 | 0.60 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.32% | 12.30% | 30.44% | 22.98% |
| Free Cash Flow Growth | -11.50% | -7.95% | -13.86% | 25.29% |
| Safety | ||||
| Net Debt / EBITDA | 0.51 | -1.61 | -1.71 | -1.89 |
| Interest Coverage | 4.70 | 20.03 | 31.05 | 77.04 |
| Efficiency | ||||
| Inventory Turnover | 136.47 | 193.84 | 192.62 | 482.83 |
| Cash Conversion Cycle | 200.01 | 161.02 | 144.56 | 129.54 |